+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021

  • Report
  • 76 Pages
  • April 2018
  • Region: Asia Pacific
  • Frost & Sullivan
  • ID: 4521810

Increasing Incidence Rates of Myocardial Infarction and Aging Population in APAC Drive the Troponin Diagnostics Market

Cardiac troponins will continue to remain the gold standard for early diagnosis of acute myocardial infarction (AMI); however, the key challenge to address is the advent of a complementary biomarker to prevent repeat diagnosis. Multiplexing platforms should be harnessed for simultaneous testing of complementary biomarkers such as H-FABP, cardiac myosin binding C protein, co-peptin, and Pentraxin 3 (PTX3) that should be combined with utmost clinical utility. Chinese Food & Drug Administration (CFDA) and regional market access to APAC countries such as Indonesia and India will emerge as key markets with early commercial access with the new proposed CE regulatory guidelines that require lengthy approval times and clinical benefits. Furthermore, with the huge market opportunities in emerging APAC countries, unlike the conventional approach APAC market, access will take a center stage in parallel with Europe and the US.

There is a general trend toward decentralization of laboratory testing in hospitals that have demonstrated an overall improvement in operational efficiency by 30% to 40%, further supported by the overall trends in pathology price cuts as an indirect measure to rising healthcare expenditure. Given the overall market trends in central lab testing, there will be a higher propensity toward adoption of POCT, with quantitative outcomes for mainstream clinical diagnosis. There will be an increase in adoption of POCT, which would eventually shrink the lab-based market for troponin biomarkers used for the diagnosis of MI.

Physicians are demanding for a more accurate test which could reduce the burden in the healthcare settings. For patients under the acute critical conditions such as myocardial infarction, fast results and quick diagnosis are required. The rising prevalence of MI and increasing morbidity in the region will fuel the growth of diagnostic testings. Moreover, demands from physicians for more accurate and sensitive results will push researchers and investments for the diagnosis of MI.

Key Issues Addressed

  • What are the key healthcare trends that could impact the APAC cardiac biomarker diagnostics market?
  • What are the market drivers and restraints that are impacting the market growth?
  • What are the unmet needs and the opportunities for the existing and emerging participants?
  • What are the segment shares of the key market participants?
  • How are companies dealing with the challenges in the market space?
  • What are the future trends and the forecast scenario of the AMI biomarkers diagnostics in a different region?

Table of Contents

1. Executive Summary
  • Key Findings
  • Scope and Segmentation
  • Key Questions This Study Will Answer
  • Market Engineering Measurements
  • Key Companies to Watch

2. Market Overview
  • Market Background
  • Cardiac Diagnostics Market Overview
  • Cardiac Biomarker Diagnostics Overview
  • Cardiac Diagnostics Overview
  • Market Overview-Testing Procedure
  • Defining Healthcare Trends in the Future

3. Competitive Playbook
  • New Market Opportunities
  • Competitive Structures
  • Notable Deals and Launches-Cardiac Biomarker Diagnostics

4. Driver and Restraints
  • Market Drivers
  • Drivers Explained
  • Market Restraints
  • Restraints Explained

5. Forecast and Discussion
  • Forecast Methodology
  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Percent Revenue Forecast Breakdown by Segments

6. Competitive Environment
  • Market Share
  • Market Share Analysis

7. Growth Opportunities
  • Major Growth Opportunities
  • Growth Opportunity Matrix
  • Growth Opportunity 1-Companion Diagnostics
  • Growth Opportunity 2-POCT in Cardiac Biomarker Diagnostics
  • Growth Opportunity 3-Integrated and Efficient System
  • Growth Opportunity 4-Digital Health and Diagnostics Inter-convergence Model
  • Strategic Imperative for Cardiac Troponins Market

8. Lab-based Segment Analysis
  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Segment Share
  • Segment Share Analysis

9. POCT Segment Analysis
  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Segment Share
  • Segment Share Analysis

10. The Last Word
  • The Last Word-3 Big Predictions
  • Legal Disclaimer

11. Appendix
  • List of Exhibits
  • List of Others Companies
  • Market Engineering Methodology